IL-6 receptor antibody treatment improves muscle weakness in experimental autoimmune myasthenia gravis mouse model

Myasthenia gravis (MG) is a chronic autoimmune disease characterized by muscle weakness and fatigue. It is caused by pathological autoantibodies against components expressed at neuromuscular junctions, such as acetylcholine receptor (AChR). Interleukin-6 (IL-6) has been suggested to play a role in t...

Full description

Bibliographic Details

Published in:	Frontiers in Neurology
Main Authors:	Shota Miyake, Kenichi Serizawa, Shinichi Onishi, Yoshichika Katsura, Masayuki Baba, Mitsue Kurasawa, Haruna Tomizawa-Shinohara, Keigo Yorozu, Yoshihiro Matsumoto, Mariko Noguchi-Sasaki
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-05-01
Subjects:	myasthenia gravis IL-6 IL-6R antibody acetylcholine receptor follicular helper T cells
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2024.1356300/full